iifl-logo

Lupin Ltd Board Meeting

2,095
(4.24%)
Apr 3, 2025|10:09:59 AM

Lupin CORPORATE ACTIONS

03/04/2024calendar-icon
03/04/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting31 Mar 202531 Mar 2025
Outcome of the Board Meeting held on March 31, 2025.
Board Meeting11 Feb 202527 Jan 2025
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended December 31 2024 and other business matters. Outcome of Board Meeting - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 12.02.2025)
Board Meeting7 Nov 202422 Oct 2024
Quarterly Results LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024. Read less.. (As Per BSE Announcement Dated on 22.10.2024) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024. (As Per BSE Announcement Dated on: 07/11/2024)
Board Meeting6 Aug 202423 Jul 2024
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2024 inter alia to consider and approve the unaudited financial results of the Company for the quarter ended June 30 2024 and other business matters.
Board Meeting6 May 202422 Apr 2024
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2024 ,inter alia, to consider and approve audited financial results of the Company for the quarter and year-ended March 31, 2024 and recommend dividend, if any. Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31, 2024 And Recommend Final Dividend @ 400% i.e. Rs. 8/- Per Equity Share Of The Face Value of Rs. 2/- Each For The Year Ended March 31, 2024. Appointment of Mr. Jeffrey Kindler and Mr. Alfonso Zulueta as Independent Directors of the Company effective May 6, 2024. (As Per BSE Announcement Dated on: 06/05/2024)

Lupin: Related News

Lupin Expands US Portfolio with USFDA Approval for Amifampridine
17 Mar 2025|10:28 PM

Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.

Read More
Top Stocks for Today - 10th March 2025
10 Mar 2025|07:25 AM

Here are some of the stocks that may see significant price movement today: IREDA, Gensol Engineering, Tata Power, etc.

Read More
Lupin’s Somerset Facility Receives USFDA EIR
24 Feb 2025|09:19 AM

The inspection covered the period from January 27 until January 31, 2025, and was used to assess cGMP and other regulatory requirements at the facility

Read More
Top Stocks for Today - 24th February 2025
24 Feb 2025|07:10 AM

Here are some of the stocks that may see significant price movement today: Bharti Airtel, Vedanta, Rail Vikas Nigam (RVNL), etc.

Read More
Lupin Secures USFDA Nod for Generic Atrovent Nasal Spray
11 Feb 2025|11:31 PM

Ipratropium Bromide Nasal Solution (0.03%) is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis.

Read More
Lupin Secures FDA Nod for First-to-File Generic HIV Drug
5 Feb 2025|09:27 AM

Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets are therapeutic equivalents of Symtuza Tablets 800 mg/150 mg/200 mg/10 mg brand of Janssen Products, LP.

Read More
Top Stocks for Today - 9th January 2025
9 Jan 2025|07:02 AM

Here are some of the stocks that may see significant price movement today: Tata Motors, BHEL, Hindalco, Lupin, etc.

Read More
Lupin Acquires Huminsulin Brand from Eli Lilly to Boost Diabetes Portfolio
31 Dec 2024|02:45 PM

Lupin was already selling Huminsulin under the license agreement entered with Lilly India.

Read More
Lupin gets USFDA approval for generic HIV tablets
19 Dec 2024|11:48 AM

The approval enables Lupin to offer a generic version of Descovy pills, which were originally produced by Gilead Sciences Inc.

Read More
Top Stocks for today - 16th December 2024
16 Dec 2024|07:20 AM

Here are some of the stocks that may see significant price movement today: Reliance Industries, Biocon, Bharat Forge, etc.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.